Sensei Biotherapeutics (NASDAQ:FTH) CFO Brian Stephenson Buys 9,230 Shares of Stock

Posted by Geri Gentry on Jun 24th, 2026

Sensei Biotherapeutics, Inc. (NASDAQ:FTH – Get Free Report) CFO Brian Stephenson purchased 9,230 shares of the stock in a transaction on Tuesday, June 23rd. The shares were purchased at an average cost of $24.36 per share, with a total value of $224,842.80. Following the transaction, the chief financial officer owned 17,413 shares of the company’s stock, valued at $424,180.68. This trade represents a 112.79% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Sensei Biotherapeutics Price Performance

NASDAQ:FTH traded up $0.54 on Wednesday, hitting $24.54. 102,858 shares of the stock were exchanged, compared to its average volume of 189,941. The firm has a market capitalization of $32.93 million, a PE ratio of -0.17 and a beta of -0.25. Sensei Biotherapeutics, Inc. has a fifty-two week low of $6.32 and a fifty-two week high of $36.76.

Sensei Biotherapeutics News Summary

Here are the key news stories impacting Sensei Biotherapeutics this week:

Positive Sentiment: HC Wainwright maintained a bullish stance on Sensei Biotherapeutics and reiterated a $60 target, which may have supported investor sentiment despite the company’s expected losses. HC Wainwright analyst report
Neutral Sentiment: The firm updated multiple earnings estimates for 2026-2030, forecasting continued losses in the near and medium term, including EPS estimates of ($0.63) for Q2 2026, ($0.69) for Q3 2026, and ($0.75) for Q4 2026. HC Wainwright earnings estimates
Neutral Sentiment: HC Wainwright also projected losses for later years, including FY2027 EPS of ($3.72), FY2028 EPS of ($3.19), FY2029 EPS of ($3.16), and FY2030 EPS of ($3.07), reflecting a long path to profitability. HC Wainwright long-term estimates

Analysts Set New Price Targets

Several research firms have recently issued reports on FTH. BTIG Research raised shares of Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, June 11th. Weiss Ratings started coverage on shares of Sensei Biotherapeutics in a report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. Finally, HC Wainwright began coverage on shares of Sensei Biotherapeutics in a research report on Monday. They set a “buy” rating and a $60.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $60.00.

Check Out Our Latest Research Report on Sensei Biotherapeutics

About Sensei Biotherapeutics

(Get Free Report)

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.